RELMADA THERAPEUTICS, INC. Accumulated Capitalized Interest Costs
RELMADA THERAPEUTICS, INC. (RLMD) had Accumulated Capitalized Interest Costs of $522.87 thousand as of 2018-10-31, per its 10-KT filed 2020-03-26.
Discontinued › Notes › Debt
us-gaap:AccumulatedCapitalizedInterestCosts · last filed 2020-03-26
- 2018-10-31: Accumulated Capitalized Interest Costs $522.87K.
| Period end | Accumulated Capitalized Interest Costs |
|---|---|
| 2018-10-31 | $522.87K 10-KT · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |